Circulating
lactate is a fuel source for liver metabolism but may exacerbate
metabolic diseases such as
nonalcoholic steatohepatitis (NASH). Indeed, haploinsufficiency of
lactate transporter monocarboxylate transporter 1 (MCT1) in mice reportedly promotes resistance to hepatic steatosis and
inflammation. Here, we used adeno-associated virus (AAV) vectors to deliver
thyroxin binding
globulin (TBG)-Cre or
lecithin-retinol acyltransferase (Lrat)-Cre to MCT1fl/fl mice on a
choline-deficient, high-fat NASH diet to deplete hepatocyte or stellate cell MCT1, respectively. Stellate cell MCT1KO (AAV-Lrat-Cre) attenuated liver
type 1 collagen protein expression and caused a downward trend in trichrome staining. MCT1 depletion in cultured human LX2 stellate cells also diminished
collagen 1
protein expression. Tetra-ethylenglycol-
cholesterol (Chol)-conjugated siRNAs, which enter all hepatic cell types, and hepatocyte-selective tri-N-acetyl
galactosamine (GN)-conjugated siRNAs were then used to evaluate MCT1 function in a genetically obese NASH mouse model. MCT1 silencing by Chol-
siRNA decreased liver
collagen 1 levels, while hepatocyte-selective MCT1 depletion by AAV-TBG-Cre or by GN-
siRNA unexpectedly increased
collagen 1 and total
fibrosis without effect on
triglyceride accumulation. These findings demonstrate that stellate cell
lactate transporter MCT1 significantly contributes to
liver fibrosis through increased
collagen 1
protein expression in vitro and in vivo, while hepatocyte MCT1 appears not to be an attractive therapeutic target for NASH.